Therapeutic proteins such as antibodies are playing an increasingly prominent role in the
treatment of numerous diseases including cancer and rheumatoid arthritis. However, these …

Therapeutic proteins such as antibodies constitute the most rapidly growing class of
pharmaceuticals for use in diverse clinical settings including cancer, chronic inflammatory …

Monoclonal antibodies represent the fastest growing class of pharmaceuticals. A major
problem, however, is that the proteins are susceptible to aggregation at the high …

Therapeutic antibodies of many different IgG subclasses (IgG1, IgG2 and IgG4) are used in
the treatment of various cancers, rheumatoid arthritis and other inflammatory and infectious …

The aggregation propensity of each particular protein seems to be shaped by evolution
according to its natural abundance in the cell. The production and downstream processing …

Protein aggregation remains a major area of focus in the production of monoclonal
antibodies. Improving the intrinsic properties of antibodies can improve manufacturability …

Protein aggregation is a hallmark of a growing number of human disorders and constitutes a
major bottleneck in the manufacturing of therapeutic proteins. Therefore, there is a strong …

Protein aggregation is a major factor limiting the biotechnological and therapeutic
application of many proteins, including enzymes and monoclonal antibodies. The molecular …

Histidine, a widely used buffer in monoclonal antibody (mAb) formulations, is known to
reduce antibody aggregation. While experimental studies suggest a nonelectrostatic …

Self-association of therapeutic monoclonal antibodies (mabs) are thought to modulate the
undesirably high viscosity observed in their concentrated solutions. Computational …